ISEV Task Force on Regulatory Affairs and Clinical Use of EV-based Therapeutics

Aim

The 'Task Force on Regulatory Affairs and Clinical Use of EV-based Therapeutics' would like to work with stakeholders from regulatory authorities, academia, clinical research and other research institutions to contribute to the development of **applicable regulatory guidance**.

We hope to jointly accelerate achieving the ultimate goal of a **safe and efficient evaluation of EVs in clinical studies** and eventually **developing proven EV-based therapeutics**. In pursuit of this goal, the Task Force and other ISEV members can serve as a valuable expert resource for basic and clinical researchers and for representatives of regulatory bodies. Here, we provide a list of interesting articles related to the aim of safe and efficient EV-Therapeutics:

Recommended Articles:

Asadpour et al 2023 – Uncovering the gray zone: mapping the global landscape of direct-to-consumer business offering interventions based on secretomes, extracellular vesicles and exosomes
https://pmc.ncbi.nlm.nih.gov/articles/PMC10156419/

Duong et al 2023 – Registered clinical trials investigating treatment with cell-derived extracellular vesicles: a scoping review
https://www.sciencedirect.com/science/article/pii/S1465324923001020?via%3Dihub